Announcements

Posted on by

Announcements

 
 
Paul G. Allen Frontiers Group    [to 18 Apr 2020]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
Press Release
No new digest content identified.
 
 
 BMGF – Gates Foundation  [to 18 Apr 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
APRIL 15, 2020
Bill & Melinda Gates Foundation Expands Commitment to Global COVID-19 Response, Calls for International Collaboration to Protect People Everywhere from the Virus
Additional funding brings foundation commitment to more than $250 million to support development of diagnostics, therapeutics, and vaccines; help strengthen African and South Asian health systems; and help mitigate the social and economic impacts of the virus.
 
 
 Bill & Melinda Gates Medical Research Institute    [to 18 Apr 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
NEWS RELEASE 4/14/20 —
Bill & Melinda Gates Medical Research Institute and the Institut Pasteur to Develop a Novel Vaccine Against Shigella
Cambridge, MA USA and Paris, FRANCE — The Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Institut Pasteur have entered into an exclusive collaboration and license agreement to jointly develop a quadrivalent synthetic carbohydrate-based conjugate vaccine against Shigella flexneri serotypes 2a, 3a, and 6 and Shigella sonnei. Gates MRI will have an exclusive license for manufacture and commercialization of the vaccine in 73 GAVI low-income countries, thereby furthering Gates MRI’s mission of preventing or mitigating infections caused by Shigella. Financial terms of the agreement were not disclosed.
 
 CARB-X   [to 18 Apr 2020]
https://carb-x.org/
 CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
 CEPI – Coalition for Epidemic Preparedness Innovations  [to 18 Apr 2020]
http://cepi.net/
Latest News
Netherlands and Switzerland join the search for COVID-19 vaccines
The total sum pledged towards the US$2 billion target now stands at US$765 million.
Blog  16 Apr 2020
IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO’s COVID-19 DNA vaccine in South Korea
CEPI grants $6.9 million to INOVIO and IVI to run clinical testing in Korea for INOVIO’s COVID-19 vaccine candidate. Korea National Institute of Health (KNIH) to support IVI’s testing efforts.
COVID-19   16 Apr 2020
 
 
Clinton Health Access Initiative, Inc. (CHAI)  [to 18 Apr 2020]
https://clintonhealthaccess.org/
News & Press Releases
No new digest content identified.
 
 
EDCTP    [to 18 Apr 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center    [to 18 Apr 2020]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 18 Apr 2020]
http://www.ema.europa.eu/ema/
News & Press Releases
News: Meeting highlights from ICMRA global regulatory workshop on COVID-19 observational studies and real world data
Last updated: 16/04/2020
Observational studies of data generated in clinical practice in the context of COVID-19 can contribute to the development, authorisation and monitoring of the safety and efficacy of medicines and vaccines to prevent and treat COVID-19. Closer collaboration between international medicines regulators and information sharing in this area will benefit patients around the world. This is highlighted in the summary of the latest global regulatory workshop on COVID-19 observational studies and real world data, organised under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), which has been published today.
   The meeting report provides a snapshot of ongoing or planned observational studies, platforms and registries in various countries and regions around the world. The studies are aimed to characterise COVID-19 disease and identify links between clinical outcomes and the use of potential treatments for COVID-19 and of concomitant medication, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor antagonists (ARBs) and non-steroidal anti-inflammatory medicines (NSAIDs). Observational studies also have the potential to generate robust evidence on the safety and effectiveness of vaccines and treatments when they are released on the market…
 
 
European Vaccine Initiative  [to 18 Apr 2020]
http://www.euvaccine.eu/news-events
Latest News
No new digest content identified.
 
 
 FDA [to 18 Apr 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
April 17, 2020 – Coronavirus (COVID-19) Update: Daily Roundup April 17, 2020
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:
:: The National Institutes of Health (NIH) and the Foundation for the NIH announced a public-private partnership with the FDA and others to speed the development of COVID-19 vaccine and treatment options. The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership also includes the U.S. Centers for Disease Control and Prevention, the European Medicines Agency, the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, as well as more than a dozen biopharmaceutical companies. The ACTIV partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.
:: Today, a federal court has entered an emergency temporary restraining order and a preliminary injunction against the Genesis II Church of Health and Healing (Genesis) and four individuals associated with the entity requiring them to immediately stop distributing its “Miracle Mineral Solution” (MMS), an unproven and potentially harmful treatment offered for sale to treat Coronavirus, which includes Coronavirus Disease 2019 (COVID-19) and many other diseases. The FDA, jointly with the Federal Trade Commission (FTC), previously issued a warning letter to Genesis and the FDA has warned consumers numerous times over the past decade not to purchase or drink chlorine dioxide products such as MMS sold as medical treatments. The FDA and FTC requested that the company respond within 48 hours describing the specific steps it has taken to correct the violations. In response to the warning letter, the defendants made clear that they had no intention of taking corrective action and would continue to sell MMS in violation of the law.
:: The FDA and FTC issued a warning letter to a seller of fraudulent COVID-19 products, as part of the agency’s effort to protect consumers. The seller warned, Nova Botanix LTD DBA CanaBD, sells unapproved and misbranded cannabidiol (CBD) products for sale in the U.S. with misleading claims that the products are safe and/or effective for the prevention and treatment of COVID-19. There are currently no FDA-approved products to prevent or treat COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.
Yesterday, FDA announced a further expansion of COVID-19 testing options through the recognition that spun synthetic swabs – with a design similar to Q-tips – could be used to test patients by collecting a sample from the front of the nose. As part of this effort, U.S. Cotton, the largest manufacturer of cotton swabs and a subsidiary of Parkdale-Mills, developed a polyester-based Q-tip-type swab that is fully synthetic for compatibility with COVID-19 testing. Harnessing its large-scale U.S.-based manufacturing capabilities, U.S. Cotton plans to produce these new polyester swabs in large quantities to help meet the needs for coronavirus diagnostic testing.
:: The FDA issued a new emergency use authorization (EUA) for Extracorporeal Blood Purification (EBP) to ExThera Medical Corporation for emergency use of the Seraph 100 Microbind Affinity Blood Filter device to treat patients 18 years of age or older with confirmed COVID-19 admitted to the intensive care unit with confirmed or imminent respiratory failure to reduce pathogens and inflammatory mediators from the bloodstream. The Seraph 100 Microbind Affinity Blood Filter device is an extracorporeal broad-spectrum sorbent hemoperfusion device that is designed to reduce bacteria, viruses, toxins, cytokines and other inflammatory mediators from whole blood. The Seraph 100 Microbind Affinity Blood Filter device is designed to share a form factor very similar to other blood filters, such as hemodialyzers or hemoperfusion filters, and therefore is compatible with hemodialysis systems that use industry standard bloodline connectors for ease of operation, training, and utility.

   :: Diagnostics update to date:
:: During the COVID-19 pandemic, the FDA has worked with more than 320 test developers who have said they will be submitting emergency use authorizations (EUA) requests to FDA for tests that detect the virus.
       :: To date, the FDA has issued 39 individual emergency use authorizations for test kit manufacturers and laboratories. In addition, 16 authorized tests have been added to the EUA letter of authorization for high complexity molecular-based laboratory developed tests (LDTs).
       :: The FDA has been notified that more than 190 laboratories have begun testing under the policies set forth in our COVID-19 Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency Guidance.
:: The FDA also continues to keep its COVID-19 Diagnostics FAQ up to date.
 
 
Fondation Merieux  [to 18 Apr 2020]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.
 
 
Gavi [to 18 Apr 2020]
https://www.gavi.org/
Top Stories
17 April 2020
Saudi Arabia pledges US$ 150 million to Gavi COVID response
:: New funding for Gavi, the Vaccine Alliance to support lower-income countries’ response to the COVID-19 pandemic, including supporting health systems by protecting health workers, providing diagnostics and improving surveillance
:: Pledge follows G20 commitment to provide immediate resources to Gavi
:: Dr Ngozi Okonjo-Iweala: “COVID-19 is a global problem which requires a global solution”
17 April 2020
Reed Hastings and Patty Quillin support Gavi with US$ 30 million donation
:: Reed Hastings and Patty Quillin donated US$ 30 million to support the Alliance’s response to COVID-19 and help protect the world against new outbreaks of other infectious diseases
:: Cash donation is the first private sector contribution towards Gavi’s drive to raise at least US$ 7.4 billion to immunise 300 million children and save 8 million lives in the next five years
:: Gavi is working to keep life-saving immunisation programmes running in the face of the COVID-19 pandemic, as well as investing hundreds of millions of dollars to help fragile health systems tackle the outbreak
 
 
GHIT Fund   [to 18 Apr 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.
 
 
Global Fund  [to 18 Apr 2020]
https://www.theglobalfund.org/en/news/
News & Stories
Funding Model
COVID-19 Response Mechanism Update for Implementing Countries
17 April 2020
Video
Community-based Monitoring
15 April 2020
 
 
Sourcing & Management of Health Products
COVID-19 Response: Impact on Health Product Supply
14 April 2020
Funding Model
COVID-19 Response: Guidance on Country Dialogue and Human Rights
14 April 2020
The Global Fund has published new guidance on country dialogue and on human rights for countries responding to the COVID-19 pandemic.
Country dialogue
The Global Fund is committed to ensuring that input from those closest to and living with HIV, tuberculosis and malaria are included in every funding request to the Global Fund. Their input is critical to ensuring that programs are effective and designed to help those most impacted.
Inclusive country dialogue and the engagement of civil society, communities, and key and vulnerable populations in the development of funding requests remains a requirement for receiving financing from the Global Fund.
To help ensure that these vital processes continue, the Global Fund has published new guidance on how to host a virtual dialogue that is inclusive and transparent:
Virtual Inclusive Dialogue download in English
 
 
 
Hilleman Laboratories   [to 18 Apr 2020]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 18 Apr 2020]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
Human Vaccines Project and Harvard T.H. Chan School of Public Health Launch New Initiative to Decode Immune System, Speed New Vaccines
Harvard Chan School-Human Vaccines Project collaboration will use artificial intelligence and causal inference to accelerate drug and vaccine development
Boston, MA – Apr 14, 2020
The Harvard T.H. Chan School of Public Health and the Human Vaccines Project announce the Human Immunomics Initiative, a joint project that aims to revolutionize the understanding of the human immune system and accelerate the creation of effective vaccines, diagnostics, and treatments. The Human Immunomics Initiative (HII) will bring together Harvard Chan School experts in epidemiology, causal inference, immunology, and computational and systems biology with the resources and expertise of the Human Vaccines Project, a global, nonprofit, human immunology-based clinical research consortium. HII will develop artificial intelligence-powered models of immunity that can be used to accelerate the design and testing of vaccines and therapeutics for a wide range of diseases…
  …The insights gained through HII will pave the way for artificial intelligence-powered models that allow researchers to virtually test potential vaccines, and predict what vaccines and therapies might work best across populations. This could massively speed up vaccine and drug development, and lower costs spent on testing and trials…
 
 
IAVI  [to 18 Apr 2020]
https://www.iavi.org/newsroom
Press Releases
No new digest content identified.
 
 
International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.
 
 
International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/
Press Releases
No new digest content identified.
 
 
IFRC   [to 18 Apr 2020]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.
 
 
IVAC  [to 18 Apr 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
Webinars: Register for World Immunization Week Series
Mark your calendars! The International Vaccine Access Center (IVAC) will host a series of webinars to celebrate World Immunization Week, April 24-30, 2020. Please register for the webinars below:
Measuring the Economic Impact of Vaccines (REGISTER HERE)
Date: April 27, 2020
Time: 12:00 PM EST
Description: The webinar will present the estimates from the Decade of Vaccine Economics (DoVE) study of the economic benefits and return-on-investment of vaccines against 10 antigens in 73 low-income countries. The webinar will begin with an overview of the methodology used to compute these estimates and then showcase how we apply these methods to calculate the return-on-investment from 2011-2020 and predict the future return-on-investment from 2021-2030.
 
 
IVI   [to 18 Apr 2020]
http://www.ivi.int/
Selected IVI News & Announcements
IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO’s COVID-19 DNA vaccine in South Korea
:: The Coalition for Epidemic Preparedness Innovations (CEPI) grants funding $6.9 million to INOVIO and IVI to conduct clinical testing in Korea for INOVIO’s COVID-19 vaccine candidate based on their well-established DNA platform technology
:: Korea National Institute of Health (KNIH) to support IVI’s testing efforts
April 16, 2020, SEOUL, Korea and PLYMOUTH MEETING, PA. USA – The International Vaccine (IVI) announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) has granted $6.9 million funding to INOVIO (NASDAQ:INO) to work with IVI and the Korea National Institute of Health (KNIH) for Phase I/II clinical trial of INOVIO’s COVID-19 vaccine candidate (INO-4800) in South Korea. IVI will conduct the trial in parallel to INOVIO’s Phase I INO-4800 study currently underway in the US since April 6, 2020 with 40 healthy adults receiving the vaccine candidate and eventually expanding to older adults…
 
 
JEE Alliance  [to 18 Apr 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 18 Apr 2020]
http://www.msf.org/
Latest [Selected Announcements]
Mediterranean migration
EU states use COVID-19 to shirk search and rescue obligations as MSF ends Ocean Viking partnership
Press Release 17 Apr 2020

Coronavirus disease COVID-19
MSF supports COVID-19 response in Cameroon
Project Update 16 Apr 2020
Coronavirus disease COVID-19
MSF working with Mali health authorities in treating COVID-19 patien…
Press Release 16 Apr 2020
France
“Access to medical care must be maintained for the most vulnerable” during …
Voices from the Field 14 Apr 2020
South Sudan
As conflict intensifies near Pibor, thousands flee into the bush
Project Update 14 Apr 2020
Coronavirus disease COVID-19
Northwest Syria will “struggle to cope in the face of the COVID-19 pandemic”
Voices from the Field 14 Apr 2020
Coronavirus disease COVID-19
MSF supports Iraqi hospitals responding to COVID-19
Project Update 14 Apr 2020
DRC Ebola outbreaks
Crisis update – April 2020
Crisis Update 14 Apr 2020
 
 
 
National Vaccine Program Office – U.S. HHS  [to 18 Apr 2020]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)
 
 
NIH  [to 18 Apr 2020]
http://www.nih.gov/news-events/news-releases
Selected News Releases
Antiviral remdesivir prevents disease progression in monkeys with COVID-19
April 17, 2020 — Study supports clinical testing under way across U.S.

  1. Williamson, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2(link is external).

Abstract
Background: Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. Methods: To evaluate the effect of remdesivir treatment on SARS-CoV-2 disease outcome, we used the recently established rhesus macaque model of SARS-CoV-2 infection that results in transient lower respiratory tract disease. Two groups of six rhesus macaques were infected with SARS-CoV-2 and treated with intravenous remdesivir or an equal volume of vehicle solution once daily. Clinical, virological and histological parameters were assessed regularly during the study and at necropsy to determine treatment efficacy. Results: In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs. Virus titers in bronchoalveolar lavages were significantly reduced as early as 12hrs after the first treatment was administered. At necropsy on day 7 after inoculation, lung viral loads of remdesivir-treated animals were significantly lower and there was a clear reduction in damage to the lung tissue. Conclusions: Therapeutic remdesivir treatment initiated early during infection has a clear clinical benefit in SARS-CoV-2-infected rhesus macaques. These data support early remdesivir treatment initiation in COVID-19 patients to prevent progression to severe pneumonia.
Investigational chimp adenovirus MERS-CoV vaccine protects monkeys
April 17, 2020 — Vaccine neutralizes multiple MERS-CoV strains.
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
April 17, 2020 — Health agencies, leading pharmaceutical companies to join forces to accelerate pandemic response.
[See COVID-19 above for detail]
NIH study validates decontamination methods for re-use of N95 respirators
April 15, 2020 — Three methods effectively sanitized masks for limited re-use.
 
 
PATH  [to 18 Apr 2020]
https://www.path.org/media-center/
Selected Announcements
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 18 Apr 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.
 
 
UNAIDS [to 18 Apr 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
17 April 2020
Community networks extend arms to connect people to medicine in Viet Nam
16 April 2020
Building peace through sustainable initiatives
15 April 2020
Keeping HIV treatment available in Pakistan during COVID-19
14 April 2020
Ratio of new HIV infections to number of people living with HIV improving
 
 
UNICEF  [to 18 Apr 2020]
https://www.unicef.org/media/press-releases
Press release
Geneva Palais briefing note on the impact of COVID-19 on children
This is a summary of what was said by UNICEF Director of the Office of Global Insight and Policy Laurence Chandy – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva.
17/04/2020
Statement
COVID-19: Global ceasefire would be a gamechanger for 250 million children living in conflict-affected areas
Statement by UNICEF Executive Director Henrietta Fore
17/04/2020
Press release
UNICEF provides vital supplies for Nigeria’s COVID-19 response
16/04/2020
Statement
UN agencies welcome first relocation of unaccompanied children from Greece
Agencies urge other EU Member States to also follow through on relocation pledges
15/04/2020
Press release
Children at increased risk of harm online during global COVID-19 pandemic
Newly released technical note aims to help governments, ICT companies, educators and parents protect children in lockdown
14/04/2020
Press release
COVID-19: UNICEF Spain contributes 418,000 protective masks to combat pandemic
Masks part of overall support procured by UNICEF Spain for the national response, including 1,050,000 gloves, 100,000 virus detection kits, 1,000 units of personal protective equipment and 97,000 units of hand sanitiser.
14/04/2020
Press release
More than 117 million children at risk of missing out on measles vaccines, as COVID-19 surges
Statement by the Measles & Rubella Initiative: American Red Cross, U.S. CDC, UNICEF, UN Foundation and WHO
13/04/2020
[See COVID-19 above for detail]
Statement
Children in detention are at heightened risk of contracting COVID-19 and should be released
Statement by UNICEF Executive Director Henrietta Fore
13/04/2020
Press release
The European Union and Belgium support UNICEF in shipping vital supplies to the Democratic Republic of the Congo
12/04/2020
 
 
Unitaid  [to 18 Apr 2020]
https://unitaid.org/#en
Unitaid is a global development agency, hosted by the World Health Organization and its major donors are France, the United Kingdom, Brazil, Norway, Chile, the Republic of Korea, Spain and the Bill & Melinda Gates Foundation.
14 April 2020
Unitaid greets World Chagas Disease Day with new analysis, new plans
Geneva – Unitaid marked the first World Chagas Disease Day with the release of a comprehensive report on how to better confront the potentially deadly parasitic infection that strikes hardest among Latin America’s poor and marginalized.
It was on this date in 1909 that a Brazilian doctor, Carlos Chagas, diagnosed the first case of what was to be called Chagas disease.
Unitaid is also developing an initiative to help eliminate mother-to-child transmission of Chagas disease as part of its mandate to improve maternal, newborn and child health…
…Unitaid’s just-released report, Technology and Market Landscape for Chagas Disease, maps out the diagnostics and treatments that are in use now and identifies innovations that could improve upon them. The report also examines market barriers that could be removed to make way for better tests and treatments…
 
 
Vaccination Acceptance Research Network (VARN)  [to 18 Apr 2020]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.
 
 
Vaccine Confidence Project  [to 18 Apr 2020]
http://www.vaccineconfidence.org/
Latest News & Archive
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 18 Apr 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 18 Apr 2020]
https://wellcome.ac.uk/news
Opinion | 16 April 2020
Greater investment is needed to help countries with the weakest health systems prepare for COVID-19
Christiane Hertz-Fowler and Georgia Walton, Infection and Immunobiology team Wellcome
We’ve awarded £12 million, in partnership with the UK Department for International Development, to speed up global COVID-19 research and development and help low- and middle-income countries prepare for the pandemic. But more investment is needed.
 
 
The Wistar Institute   [to 18 Apr 2020]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.
 
 
WFPHA: World Federation of Public Health Associations  [to 18 Apr 2020]
https://www.wfpha.org/
Latest News
WFPHA Press Release: Urge The Government of The USA to Reconsider President Trump’s Decision on WHO
Friday, 17 April 2020
The World Federation of Public Health Associations (WFPHA) deplores the decision by President Trump to suspend funding…
 
 
Call for a Coordinated, Equitable, and Human Rights-based Global Response to COVID-19
Friday, 17 April 2020
WFPHA has signed Call for Global Action Plan on COVID-19. The undersigned 99 organizations and 40 individuals call upon heads of state and government of G20 countries to ensure a robust, coordinated global response to the coronavirus disease 2019 (COVID-19) pandemic that is humane, equitable, based in the universality of human rights, and meets the needs of countries and people who are most vulnerable and have the fewest resources.
Alliance of Public Health Associations of the Americas – APHAA Declaration on COVID-19 Pandemic
Tuesday, 14 April 2020
Alliance of Public Health Associations of the Americas (APHAA) Declaration on the Situation of the COVID-19 Pandemic in the World…
 
 
World Organisation for Animal Health (OIE)   [to 18 Apr 2020]
https://www.oie.int/en/for-the-media/press-releases/2020/
Press Releases
No new digest content identified.
::::::
 
 
ARM [Alliance for Regenerative Medicine]  [to 18 Apr 2020]
https://alliancerm.org/press-releases/
Press Releases
No new digest content identified.
 
 
BIO    [to 18 Apr 2020]
https://www.bio.org/press-releases
Press Releases
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 18 Apr 2020]
http://www.dcvmn.org/
News
No new digest content identified.
 
 
IFPMA   [to 18 Apr 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
IFPMA Backgrounder – COVID-19
16 April 2020
[See COVID-19 above for detail]
 
 
PhRMA    [to 18 Apr 2020]
http://www.phrma.org/
Selected Press Releases, Statements
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
Stephen J. Ubl   |     April 15, 2020
As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have teamed up to create programs empowering employees with medical and laboratory expertise to completely or partially pause their current roles and volunteer their medical skills to help their local health care organizations…
 
 
Industry Watch
:: Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
April 16, 2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda…
Sir Andrew Witty to Take Leave of Absence From UnitedHealth Group to Co-lead World Health Organization Efforts to Accelerate a COVID-19 Vaccine
April 15, 2020